Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells

(2022) Federico Costanzo et al.   EMBO Molecular Medicine

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

(2022) Zsolt Megyesfalvi et al.   JOURNAL OF PATHOLOGY

In‐depth proteomic analysis reveals unique subtype‐specific signatures in human small‐cell lung cancer

(2022) Beáta Szeitz et al.   Clinical and Translational Medicine

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

Small-cell lung cancer

(2021) Charles M. Rudin et al.   Nature Reviews Disease Primers

Molecular profiles of small cell lung cancer subtypes: therapeutic implications

(2021) Anna Schwendenwein et al.   Molecular Therapy-Oncolytics

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses

(2021) Erik H. Knelson et al.   Cancers

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

(2021) Apar Kishor P. Ganti et al.   Journal of the National Comprehensive Cancer Network

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

(2020) Carolane Seiller et al.   Cell Death & Disease

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

(2020) Yuto Yasuda et al.   Cell Death & Disease

Advances in Small-Cell Lung Cancer (SCLC) Translational Research

(2020) Benjamin J. Drapkin et al.   Cold Spring Harbor Perspectives in Medicine

Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization

(2020) Marina K. Baine et al.   Journal of Thoracic Oncology

Immunotherapy in Small Cell Lung Cancer

(2020) Giovanna Esposito et al.   Cancers

Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives

(2020) Magdalena Kuras et al.   JOURNAL OF PROTEOME RESEARCH

BCL2 blockade overcomes MCL1 resistance in multiple myeloma

(2019) Ka Tat Siu et al.   LEUKEMIA

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

(2019) Dana Prukova et al.   CLINICAL CANCER RESEARCH

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

(2019) Esperanza M Algarín et al.   HAEMATOLOGICA

ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma

(2018) Yujie Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells

(2018) Justine Debernardi et al.   ONCOGENE

Targeting BCL-2 regulated apoptosis in cancer

(2018) Kirsteen J. Campbell et al.   Open Biology

Managing Patients With Relapsed Small-Cell Lung Cancer

(2018) Jun Gong et al.   Journal of Oncology Practice

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

(2018) Natasha S. Anstee et al.   CELL DEATH AND DIFFERENTIATION

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

(2018) Viktoria Laszlo et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

(2017) Szilvia Torok et al.   Theranostics

SCLC–State of the Art and What Does the Future Have in Store?

(2016) Kathrin Kahnert et al.   Clinical Lung Cancer

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

(2015) R. Pan et al.   BLOOD

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

(2014) V. Fresquet et al.   BLOOD

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

(2014) A. Augustyn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death

(2012) Chaitali Dutta et al.   CANCER RESEARCH

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

(2010) Carol Kilkenny et al.   PLOS BIOLOGY